Your browser doesn't support javascript.
loading
Clinical Variability in Spinal Muscular Atrophy Type III.
Coratti, Giorgia; Messina, Sonia; Lucibello, Simona; Pera, Maria Carmela; Montes, Jacqueline; Pasternak, Amy; Bovis, Francesca; Exposito Escudero, Jessica; Mazzone, Elena Stacy; Mayhew, Anna; Glanzman, Allan M; Young, Sally Dunaway; Salazar, Rachel; Duong, Tina; Muni Lofra, Robert; De Sanctis, Roberto; Carnicella, Sara; Milev, Evelin; Civitello, Matthew; Pane, Marika; Scoto, Mariacristina; Bettolo, Chiara Marini; Antonaci, Laura; Frongia, Annalia; Sframeli, Maria; Vita, Gian Luca; D'Amico, Adele; Van Den Hauwe, Marleen; Albamonte, Emilio; Goemans, Nathalie; Darras, Basil T; Bertini, Enrico; Sansone, Valeria; Day, John; Nascimento Osorio, Andres; Bruno, Claudio; Muntoni, Francesco; De Vivo, Darryl C; Finkel, Richard S; Mercuri, Eugenio.
Afiliação
  • Coratti G; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Messina S; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Lucibello S; Department of Clinical and Experimental Medicine and Centro Clinico Nemo Sud, University of Messina, Messina, Italy.
  • Pera MC; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Montes J; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Pasternak A; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Bovis F; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Exposito Escudero J; Departments of Rehabilitation and Regenerative Medicine and Neurology, Columbia University Irving Medical Center, New York, NY.
  • Mazzone ES; Departments of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Mayhew A; Department of Health Sciences (DISSAL), University of Genova, Genoa, Italy.
  • Glanzman AM; Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Déu, ISCIII, CIBERER, Barcelona, Spain.
  • Young SD; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Salazar R; The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Duong T; Department of Physical Therapy, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Muni Lofra R; Department of Neurology, Stanford University, Stanford, CA.
  • De Sanctis R; Department of Clinical and Experimental Medicine and Centro Clinico Nemo Sud, University of Messina, Messina, Italy.
  • Carnicella S; Department of Neurology, Stanford University, Stanford, CA.
  • Milev E; The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Civitello M; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Pane M; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Scoto M; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, UK.
  • Bettolo CM; Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN.
  • Antonaci L; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Frongia A; Dubowitz Neuromuscular Centre, UCL Institute of Child Health & Great Ormond Street Hospital, London, UK.
  • Sframeli M; The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Vita GL; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • D'Amico A; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Van Den Hauwe M; Pediatric Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Albamonte E; Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Goemans N; Department of Clinical and Experimental Medicine and Centro Clinico Nemo Sud, University of Messina, Messina, Italy.
  • Darras BT; Department of Clinical and Experimental Medicine and Centro Clinico Nemo Sud, University of Messina, Messina, Italy.
  • Bertini E; Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • Sansone V; Department of Child Neurology, University Hospitals Leuven, Leuven, Belgium.
  • Day J; Neurorehabilitation Unit, University of Milan, Neuromuscular Omnicentre Clinical Center, Niguarda Hospital, Milan, Italy.
  • Nascimento Osorio A; Department of Child Neurology, University Hospitals Leuven, Leuven, Belgium.
  • Bruno C; Departments of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
  • Muntoni F; Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
  • De Vivo DC; Neurorehabilitation Unit, University of Milan, Neuromuscular Omnicentre Clinical Center, Niguarda Hospital, Milan, Italy.
  • Finkel RS; Department of Neurology, Stanford University, Stanford, CA.
  • Mercuri E; Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Déu, ISCIII, CIBERER, Barcelona, Spain.
Ann Neurol ; 88(6): 1109-1117, 2020 12.
Article em En | MEDLINE | ID: mdl-32926458
ABSTRACT

OBJECTIVE:

We report natural history data in a large cohort of 199 patients with spinal muscular atrophy (SMA) type III assessed using the Hammersmith Functional Motor Scale Expanded (HFMSE). The aim of the study was to establish the annual rate and possible patterns of progression according to a number of variables, such as age of onset, age at assessment, SMN2 copy number, and functional status.

METHODS:

HFMSE longitudinal changes were assessed using piecewise linear mixed-effects models. The dependency in the data due to repeated measures was accounted for by a random intercept per individual and an unstructured covariance R matrix was used as correlation structure. An additional descriptive analysis was performed for 123 patients, for a total of 375 12-month assessments.

RESULTS:

A break point at age 7 years was set for the whole cohort and for SMA IIIA and IIIB. Age, SMA type, and ambulatory status were significantly associated with changes in mean HFMSE score, whereas gender and SMN2 copy number were not. The increase in response before the break point of age 7 years is significant only for SMA IIIA (ß = 1.79, p < 0.0001). After the break point, the change in the rate of HFMSE score significantly decrease for both SMA IIIA (ß = -1.15, p < 0.0001) and IIIB (ß = -0.69, p = 0.002).

INTERPRETATION:

Our findings contribute to the understanding of the natural history of SMA type III and will be helpful in the interpretation of the real-world data of patients treated with commercially available drugs. ANN NEUROL 2020;881109-1117.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atrofias Musculares Espinais da Infância Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Atrofias Musculares Espinais da Infância Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália